中新网评：假洋膏药年销过亿元，平台监管不能失灵

Group 1 - The article highlights the issue of false advertising related to the "Shiye Doctor" brand of medicated plasters, which claimed to have miraculous healing properties and achieved over one million sales online despite being produced domestically at a low cost of 2 yuan per box [1] - The so-called "Tokyo Medical Research Institute" is identified as a shell company registered in Hong Kong, and the image of a Japanese doctor on the product is actually a self-portrait of the owner [1] - Despite facing penalties from market regulatory authorities, the product continues to generate significant revenue, exceeding 100 million yuan in sales, raising concerns about regulatory oversight and the motivations of the sellers [1] Group 2 - E-commerce and short video platforms are criticized for their lax scrutiny of merchant qualifications and product claims, leading to rampant false advertising [2] - The imbalance between economic interests and responsibilities on these platforms results in a failure to protect consumer rights and disrupts market order, as consumers are misled by false claims [2] - In August, regulatory bodies issued clearer guidelines for medical advertising, yet deceptive practices persist, indicating that platforms must take greater responsibility in enforcing compliance [2] Group 3 - Regulatory authorities are urged to enhance supervision of platforms, ensuring they enforce strict qualifications for online stores and manage violations effectively [3] - There is a call for increased penalties for false advertising to deter such practices and protect consumer rights [3] - Collaboration between regulatory bodies and platform companies is essential to create a cleaner market environment and prevent consumer exploitation by fraudulent products [3]